EGFR and colorectal carcinoma: The addition of these targeted therapies to cytotoxic agents improve the clinical outcomes including progression-free survival (PFS) and overall survival (OS) in patients with mCRC compared to cytotoxic agents alone and represents some of the first applications of targeted therapies in oncology.15,16 This review summarizes the development of anti-EGFR therapies, specifically cetuximab-based regimens for the management of advanced CRC and highlights contexts in which these drugs continue to be developed.